Statins in lipid-lowering therapy

Hai Lu Zhao, G. Neil Thomas, Wilson Y S Leung, Brian Tomlinson, Ming Hsiung Hsieh, Paul Chan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The discovery of the inhibitors of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase (so called statins) is a great step forward in clinical pharmacology and therapeutics. Substantial clinical evidence suggests that statins are effective in the primary and secondary prevention of coronary heart disease (CHD) and stroke. Recent well-controlled clinical studies also suggest the long-term usage of statins is sale in terms of all causes of mortality, including cancers. The incidence of myopathy, which is a concern of most physicians, is relatively low from new clinical evidence. The effectiveness of statins for prevention of CHD also is shown in diabetics. The mechanisms of prevention of CHD by statins are multifactorial, including reversal of endothelial dysfunction. The cost-effectiveness of using statins in the treatment of CHD and stroke is obvious, which should encourage primary care physicians to treat those patients who need lipid-lowering therapy.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalActa Cardiologica Sinica
Volume19
Issue number1
Publication statusPublished - Mar 2003

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Coronary Disease
Therapeutics
Stroke
Clinical Pharmacology
Primary Care Physicians
Muscular Diseases
Primary Prevention
Secondary Prevention
Cost-Benefit Analysis
Oxidoreductases
Physicians
Mortality
Incidence
Neoplasms

Keywords

  • Coronary heart disease
  • Effectiveness
  • Safety
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Zhao, H. L., Thomas, G. N., Leung, W. Y. S., Tomlinson, B., Hsieh, M. H., & Chan, P. (2003). Statins in lipid-lowering therapy. Acta Cardiologica Sinica, 19(1), 1-11.

Statins in lipid-lowering therapy. / Zhao, Hai Lu; Thomas, G. Neil; Leung, Wilson Y S; Tomlinson, Brian; Hsieh, Ming Hsiung; Chan, Paul.

In: Acta Cardiologica Sinica, Vol. 19, No. 1, 03.2003, p. 1-11.

Research output: Contribution to journalArticle

Zhao, HL, Thomas, GN, Leung, WYS, Tomlinson, B, Hsieh, MH & Chan, P 2003, 'Statins in lipid-lowering therapy', Acta Cardiologica Sinica, vol. 19, no. 1, pp. 1-11.
Zhao HL, Thomas GN, Leung WYS, Tomlinson B, Hsieh MH, Chan P. Statins in lipid-lowering therapy. Acta Cardiologica Sinica. 2003 Mar;19(1):1-11.
Zhao, Hai Lu ; Thomas, G. Neil ; Leung, Wilson Y S ; Tomlinson, Brian ; Hsieh, Ming Hsiung ; Chan, Paul. / Statins in lipid-lowering therapy. In: Acta Cardiologica Sinica. 2003 ; Vol. 19, No. 1. pp. 1-11.
@article{496a8cd5ba484936aaee177f68c27763,
title = "Statins in lipid-lowering therapy",
abstract = "The discovery of the inhibitors of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase (so called statins) is a great step forward in clinical pharmacology and therapeutics. Substantial clinical evidence suggests that statins are effective in the primary and secondary prevention of coronary heart disease (CHD) and stroke. Recent well-controlled clinical studies also suggest the long-term usage of statins is sale in terms of all causes of mortality, including cancers. The incidence of myopathy, which is a concern of most physicians, is relatively low from new clinical evidence. The effectiveness of statins for prevention of CHD also is shown in diabetics. The mechanisms of prevention of CHD by statins are multifactorial, including reversal of endothelial dysfunction. The cost-effectiveness of using statins in the treatment of CHD and stroke is obvious, which should encourage primary care physicians to treat those patients who need lipid-lowering therapy.",
keywords = "Coronary heart disease, Effectiveness, Safety, Statin",
author = "Zhao, {Hai Lu} and Thomas, {G. Neil} and Leung, {Wilson Y S} and Brian Tomlinson and Hsieh, {Ming Hsiung} and Paul Chan",
year = "2003",
month = "3",
language = "English",
volume = "19",
pages = "1--11",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "1",

}

TY - JOUR

T1 - Statins in lipid-lowering therapy

AU - Zhao, Hai Lu

AU - Thomas, G. Neil

AU - Leung, Wilson Y S

AU - Tomlinson, Brian

AU - Hsieh, Ming Hsiung

AU - Chan, Paul

PY - 2003/3

Y1 - 2003/3

N2 - The discovery of the inhibitors of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase (so called statins) is a great step forward in clinical pharmacology and therapeutics. Substantial clinical evidence suggests that statins are effective in the primary and secondary prevention of coronary heart disease (CHD) and stroke. Recent well-controlled clinical studies also suggest the long-term usage of statins is sale in terms of all causes of mortality, including cancers. The incidence of myopathy, which is a concern of most physicians, is relatively low from new clinical evidence. The effectiveness of statins for prevention of CHD also is shown in diabetics. The mechanisms of prevention of CHD by statins are multifactorial, including reversal of endothelial dysfunction. The cost-effectiveness of using statins in the treatment of CHD and stroke is obvious, which should encourage primary care physicians to treat those patients who need lipid-lowering therapy.

AB - The discovery of the inhibitors of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase (so called statins) is a great step forward in clinical pharmacology and therapeutics. Substantial clinical evidence suggests that statins are effective in the primary and secondary prevention of coronary heart disease (CHD) and stroke. Recent well-controlled clinical studies also suggest the long-term usage of statins is sale in terms of all causes of mortality, including cancers. The incidence of myopathy, which is a concern of most physicians, is relatively low from new clinical evidence. The effectiveness of statins for prevention of CHD also is shown in diabetics. The mechanisms of prevention of CHD by statins are multifactorial, including reversal of endothelial dysfunction. The cost-effectiveness of using statins in the treatment of CHD and stroke is obvious, which should encourage primary care physicians to treat those patients who need lipid-lowering therapy.

KW - Coronary heart disease

KW - Effectiveness

KW - Safety

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=0038612802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038612802&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0038612802

VL - 19

SP - 1

EP - 11

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 1

ER -